Synercid Articles
Small number of combination drugs reaching the Japanese market
24 September 2007
Fujisawa launches Synercid in Japan
19 May 2003
Tokyo pharma stocks - week to May 12
19 May 2003
King buys Aventis drug rights for $200M
6 January 2003
Tokyo pharma stocks - week to April 22
29 April 2002
Aventis to sell Synercid in Japan
15 November 2001
Pharmacia downplays Zyvox resistance
17 April 2001
Synercid effective in vancomycin-resistant ICU infections
7 December 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
First Aventis approval, for Synercid
24 December 1999
Rhone-Poulenc's novel antibiotic Synercid approved in the USA
22 September 1999
First launch for R-PR's Synercid
2 September 1999
R-PR's Synercid approved in first market, the UK
5 August 1999
31% Boost For "Superbug" Funds
5 January 1999
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
Hoechst & Rhone-Poulenc Merge To Create Aventis
1 December 1998
R-PR's Synercid Backed By FDA Panel
24 February 1998
High Hopes For New Products At Rhone-Poulenc
5 February 1998
New Products In 1998; A Look Ahead
6 January 1998
Euro Filing For Synercid
2 October 1997
R-PR Files First Dossier For Synercid Antibiotic
10 September 1997
New Data With R-PR's Synercid
10 July 1997
New Data With R-PR's Synercid
8 July 1997
FDA Year-End Approval Spate As Expected
6 January 1997
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
R-PR Divulges R&D Pipeline Developments
23 September 1996
New R-PR Anti-Infective Targets Severe Infections
12 February 1996
R-PR's Synercid news
18 December 1995
R-PR Starts Fisons R&D Integration; Product Update
4 December 1995
Synercid And Listeriosis
3 April 1995
R-PR Looks To New Products For Growth
20 February 1995
RHONE-POULENC RORER'S FOCUSED R&D PIPELINE
7 June 1993
Showing 1-38 of 38 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
